Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Beneficial Ownership Report · SCHEDULE 13G/A

Capricor Therapeutics, Inc.

CAPRNASDAQEQUITYCurrent

Beneficial Ownership Report

Filed Nov 16, 2026Accepted Nov 16, 2026, 4:15 PM ESTFiling CIK 1232621Accession 0001214659-26-014413
Share

Structured filing — SCHEDULE 13G/A

primary_doc.xml

Open full document ↗

Amendment · This filing reports the amendment as submitted.

Subject company

Company
Capricor Therapeutics, Inc.
Company CIK
0001133869
Street
10865 Road to the Cure
Street (continued)
Suite 150
City
San Diego
State / country code
CA
Postal code
92121

Statement details

Amendment number
2
Security class
Common Stock, par value $0.001 per share
Event date
09/30/2026
Rule designation
Rule 13d-1(c)

Reporting person 1

Name
TANG CAPITAL MANAGEMENT, LLC
Citizenship / organization
DE
Reporting person type
OO
Aggregate amount owned
0.00
Percent of class
0
Sole voting power
0.00
Shared voting power
0.00
Sole dispositive power
0.00
Shared dispositive power
0.00
Aggregate excludes certain shares
N

Reporting person 2

Name
KEVIN TANG
Citizenship / organization
X1
Reporting person type
IN
Aggregate amount owned
0.00
Percent of class
0
Sole voting power
0.00
Shared voting power
0.00
Sole dispositive power
0.00
Shared dispositive power
0.00
Aggregate excludes certain shares
N

Reporting person 3

Name
TANG CAPITAL PARTNERS, LP
Citizenship / organization
DE
Reporting person type
PN
Aggregate amount owned
0.00
Percent of class
0
Sole voting power
0.00
Shared voting power
0.00
Sole dispositive power
0.00
Shared dispositive power
0.00
Aggregate excludes certain shares
N

Reporting person 4

Name
TANG CAPITAL PARTNERS INTERNATIONAL, LP
Citizenship / organization
DE
Reporting person type
PN
Aggregate amount owned
0.00
Percent of class
0
Sole voting power
0.00
Shared voting power
0.00
Sole dispositive power
0.00
Shared dispositive power
0.00
Aggregate excludes certain shares
N

Reporting person 5

Name
TANG CAPITAL PARTNERS III, INC
Citizenship / organization
NV
Reporting person type
CO
Aggregate amount owned
0.00
Percent of class
0
Sole voting power
0.00
Shared voting power
0.00
Sole dispositive power
0.00
Shared dispositive power
0.00
Aggregate excludes certain shares
N

Reporting person 6

Name
TANG CAPITAL PARTNERS IV, INC
Citizenship / organization
NV
Reporting person type
CO
Aggregate amount owned
0.00
Percent of class
0
Sole voting power
0.00
Shared voting power
0.00
Sole dispositive power
0.00
Shared dispositive power
0.00
Aggregate excludes certain shares
N

Item 1

Issuer

Capricor Therapeutics, Inc.

Principal executive office address

10865 Road to the Cure, Suite 150, San Diego, CA, 92121

Item 2

Citizenship

TCM is a Delaware limited liability company. Mr. Tang is a United States citizen. TCP and TCPI is a Delaware limited partnership. TCP III and TCP IV are Nevada corporations that are indirectly wholly owned by TCP.

Filing person

This Statement on Schedule 13G (this "Statement") is filed by Tang Capital Management, LLC ("TCM"), the general partner of Tang Capital Partners, LP ("TCP") and Tang Capital Partners International, LP ("TCPI"); Kevin Tang, the manager of TCM and Chief Executive Officer of Tang Capital Partners III, Inc. ("TCP III") and Tang Capital Partners IV, Inc. ("TCP IV"); TCP; TCPI; TCP III; and TCP IV.

Principal business or residence address

The address of TCM, Kevin Tang and TCP is 4747 Executive Drive, Suite 210, San Diego, CA 92121. The address of TCP III and TCP IV is 400 S. 4th Street, 3rd Floor, Las Vegas, NV 89101.

Item 3

Not applicable indication

Y

Item 4

Percent of class

0

Amount beneficially owned

0

Sole voting power

0 shares

Shared voting power

0 shares

Sole dispositive power

0 shares

Shared dispositive power

0 shares

Item 5

Not applicable indication

N

Ownership of 5% or less

Y

Item 6

Not applicable indication

Y

Item 7

Not applicable indication

Y

Item 8

Not applicable indication

Y

Item 9

Not applicable indication

Y

Item 10

Not applicable indication

N

Certifications

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

Signature 1

Reporting person
TANG CAPITAL MANAGEMENT, LLC
Signed
/s/ Kevin Tang
Title
Manager
Date
11/16/2026

Signature 2

Reporting person
KEVIN TANG
Signed
/s/ Kevin Tang
Title
Self
Date
11/16/2026

Signature 3

Reporting person
TANG CAPITAL PARTNERS, LP
Signed
/s/ Kevin Tang
Title
Manager, Tang Capital Management, LLC, General Partner
Date
11/16/2026

Signature 4

Reporting person
TANG CAPITAL PARTNERS INTERNATIONAL, LP
Signed
/s/ Kevin Tang
Title
Manager, Tang Capital Management, LLC, General
Date
11/16/2026

Signature 5

Reporting person
TANG CAPITAL PARTNERS III, INC
Signed
/s/ Kevin Tang
Title
Chief Executive Officer
Date
11/16/2026

Signature 6

Reporting person
TANG CAPITAL PARTNERS IV, INC
Signed
/s/ Kevin Tang
Title
Chief Executive Officer
Date
11/16/2026

Company context

Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing cell and exosome-based therapeutics for the treatment of rare diseases. Our lead product candidate, Deramiocel, is an allogeneic cardiac-derived cell therapy in late-stage development for the treatment of Duchenne muscular dystrophy, evaluated in clinical studies for its potential to preserve skeletal and cardiac muscle function. Capricor is also advancing its proprietary StealthX™ exosome platform for the targeted delivery of oligonucleotides, proteins, and small-molecule therapeutics across a range of diseases. At Capricor, we are committed to delivering new therapies for patients with rare diseases. For more information, visit capricor.com, and follow Capricor on Facebook, Instagram and X.

Current securities

Historical securities (1)

Recent company filings

  1. 10-Q filingNov 10, 2026
  2. Results of Operations and Financial ConditionNov 10, 2026
  3. SCHEDULE 13G - filed by MILLENNIUM MANAGEMENT LLC regarding CAPRICOR THERAPEUTICS, INC.Sep 14, 2026
  4. Other EventsAug 24, 2026
  5. SCHEDULE 13G - filed by MILLENNIUM MANAGEMENT LLC regarding CAPRICOR THERAPEUTICS, INC.Aug 19, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.